How do drugs like Ozempic or Wegovy (semaglutide) cause weight loss? What happens when someone comes off of these drugs? In this episode, we discuss how these drugs (GLP-1 receptor agonists) target specific areas in the brain to suppress appetite and facilitate weight loss. We also discuss clinical trials data suggesting that these drugs and/or the weight loss that they facilitate may have cardioprotective effects. Lastly, we will also examine evidence regarding weight regain when coming off of these drugs and common side effects.
References
Martynova, Y., P. B. Martinez de Morentin, J. Rochford, and L. Heisler. 2022. “Function of Neuropeptide Y within the Nucleus of the Solitary Tract in Food Intake.” The Proceedings of the Nutrition Society 81 (OCE1): E39.
Fry, Mark, and Alastair V. Ferguson. 2009. “Ghrelin Modulates Electrical Activity of Area Postrema Neurons.” American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 296 (3): R485–92.
Miller, Gary D. 2019. “Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity.” American Journal of Lifestyle Medicine 13 (6): 586–601.
Shirazi, Rozita, Vilborg Palsdottir, Jim Collander, Fredrik Anesten, Heike Vogel, Fanny Langlet, Alexander Jaschke, et al. 2013. “Glucagon-like Peptide 1 Receptor Induced Suppression of Food Intake, and Body Weight Is Mediated by Central IL-1 and IL-6.” Proceedings of the National Academy of Sciences of the United States of America 110 (40): 16199–204.
Shukla, Arun K. 2019. Chemical and Synthetic Biology Approaches to Understand Cellular Functions – Part B. Academic Press.
Gabery, Sanaz, Casper G. Salinas, Sarah J. Paulsen, Jonas Ahnfelt-Rønne, Tomas Alanentalo, Arian F. Baquero, Stephen T. Buckley, et al. 2020. “Semaglutide Lowers Body Weight in Rodents via Distributed Neural Pathways.” JCI Insight 5 (6). https://doi.org/10.1172/jci.insight.133429.
Krieger, Jean-Philippe, Myrtha Arnold, Klaus G. Pettersen, Pius Lossel, Wolfgang Langhans, and Shin J. Lee. 2016. “Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia.” Diabetes 65 (1): 34–43.
Masaki, Takayuki, Yoshinori Ozeki, Yuichi Yoshida, Mitsuhiro Okamoto, Shotaro Miyamoto, Koro Gotoh, and Hirotaka Shibata. 2022. “Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients.” Metabolites 12 (2). https://doi.org/10.3390/metabo12020147.
Secher, Anna, Jacob Jelsing, Arian F. Baquero, Jacob Hecksher-Sørensen, Michael A. Cowley, Louise S. Dalbøge, Gitte Hansen, et al. 2014. “The Arcuate Nucleus Mediates GLP-1 Receptor Agonist Liraglutide-Dependent Weight Loss.” The Journal of Clinical Investigation 124 (10): 4473–88.
Wilding, John P. H., Rachel L. Batterham, Salvatore Calanna, Melanie Davies, Luc F. Van Gaal, Ildiko Lingvay, Barbara M. McGowan, et al. 2021. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” The New England Journal of Medicine 384 (11): 989–1002.
Garvey, W. Timothy, Rachel L. Batterham, Meena Bhatta, Silvio Buscemi, Louise N. Christensen, Juan P. Frias, Esteban Jódar, et al. 2022. “Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial.” Nature Medicine 28 (10): 2083–91.
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., … & STEP 4 Investigators. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. Jama, 325(14), 1414-1425. [1] Wilding, John P. H., Rachel L. Batterham, Melanie Davies, Luc F. Van Gaal, Kristian Kandler, Katerina Konakli, Ildiko Lingvay, et al. 2022. “Weight Regain and Cardiometabolic Effects after Withdrawal of Semaglutide: The STEP 1 Trial Extension.” Diabetes, Obesity & Metabolism 24 (8): 1553–64.